Determination of glufosfamide in rat plasma by liquid chromatography/tandem mass spectrometry.
暂无分享,去创建一个
[1] G. Giaccone,et al. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. , 2004, European Journal of Cancer.
[2] D. Lacombe,et al. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. , 2003, European journal of cancer.
[3] P. Beale,et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Koepsell,et al. Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[5] W. Hull,et al. Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent β-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H]-thymidine in various tissues of the rat , 1996, Cancer Chemotherapy and Pharmacology.